Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) Attends 31st Annual ROTH Conference
Hancock Jaffe Laboratories (NASDAQ: HJLI) specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValve, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. For more information, visit the company's website at www.HancockJaffe.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news…







